You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

LOXITANE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOXITANE?
  • What are the global sales for LOXITANE?
  • What is Average Wholesale Price for LOXITANE?
Summary for LOXITANE
Drug patent expirations by year for LOXITANE
Recent Clinical Trials for LOXITANE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mylan PharmaceuticalsPhase 1

See all LOXITANE clinical trials

US Patents and Regulatory Information for LOXITANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Branded Pharm LOXITANE loxapine succinate CAPSULE;ORAL 017525-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Branded Pharm LOXITANE loxapine succinate TABLET;ORAL 017525-008 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Branded Pharm LOXITANE loxapine succinate CAPSULE;ORAL 017525-004 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Teva Branded Pharm LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOXITANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Branded Pharm LOXITANE loxapine succinate CAPSULE;ORAL 017525-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Teva Branded Pharm LOXITANE loxapine succinate CAPSULE;ORAL 017525-004 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Teva Branded Pharm LOXITANE loxapine succinate CAPSULE;ORAL 017525-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Teva Branded Pharm LOXITANE loxapine succinate CAPSULE;ORAL 017525-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for LOXITANE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1389098 SPC/GB13/055 United Kingdom ⤷  Sign Up PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220
1389098 300609 Netherlands ⤷  Sign Up PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098 2013C/054 Belgium ⤷  Sign Up PRODUCT NAME: LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225
1389098 C300609 Netherlands ⤷  Sign Up PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.